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and SSc pts with interstitial lung disease (ILD) and high systolic pulmo-
nary artery pressure (PAP). A linear negative correlation between the
high hybrid M1/M2 cell percentage and diffusing capacity of the lungs for
carbon monoxide (DLCO)% and the forced vital capacity (FVC)/DLCO
ratio higher than 1.5 was observed. No significant correlations were
reported with SSc duration, other treatments, NVC patterns, renal artery
resistive index, heart and kidney involvements, digital ulcers, telangiecta-
sias, calcinosis.
Conclusion: The study identified a circulating cell population expressing
both M1 and M2 surface markers, which is increased together with circu-
lating M2 cells in SSc pts, in particular affected by ILD and high PAP,
suggesting their possible involvement in the pathogenesis of those dis-
ease complications. Further evaluations are in progress.
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Background: Systemic Sclerosis (SSc) is a connective tissue disease,
characterized by endothelial dysfunction and fibrosis, potentially affecting
internal organs and reducing life expectancy. Digital ulcers (DUs), as well
as hand and face skin thickening, are the hallmarks of the disease.
These alterations lead to pain, functional impairment, aesthetic damages,
and psychological distress. Autologous fat grafting (AFG) is a surgical
technique used also to promote tissue regeneration. In the last decade,
AFG has been successfully developed to treat clinical conditions charac-
terized by skin atrophy or fibrosis. AFG composition of multipotent cells,
carrying angiogenic, and immunogenic properties, may be able to restore
the damaged tissues.
Objectives: Evaluate our experience with AFG to treat and prevent dam-
age and disability due to DUs and SSc skin complications.
Methods: We analyzed 25 SSc patients, extrapolated from a larger series
of 45 subjects, complaining about mouth and/or hand impairment, due to
skin involvement, and, in some cases, long-lasting DUs (M/F 6/19, mean
age 55.69±9.25-SD-years, mean disease duration 184.68±121.09-SD-
months, L/D cutaneous subsets 21/4). Surgical procedures consisted in
the injection of centrifuged and purified autologous fat, harvested from
hips or abdomen. 2ml of fat were grafted in each of the 8 sites around
the mouth, while 0.5 or 1 ml around the neurovascular bundle at the
base of each finger. The study included: preoperative data collection; 2
or 3 surgical sessions at a distance of 6 months one from the other;
data collection at 3 months after each surgical session; data collection at
3 and 6 months of follow up-FU after the last surgical procedure. Data
collection consisted of clinic-serological SSc features and clinimetric meas-
ures about hand and mouth, if present DUs were assessed as well. Fur-
thermore, patients were asked to fill in questionnaires in order to express
their level of satisfaction with hand and mouth functionality.
Results: Overall 63 surgical procedures were performed. After 1 to 3 pro-
cedures, patients reported an improvement of perioral skin tension
(p=0.0238) and a reduced dry mouth feeling (p=0.0269). Similarly,
patients stated an improvement of hands tension (p=0.0037). Furthermore,
we observed a complete healing of DUs in 8/9 patients (p=0.0297).
These positive clinical changes were mirrored by a subjective ameliora-
tion. In particular, pain decreased, evaluated by short-form McGill Pain
Questionnaire (SF-MPQ), scrutinizing sensory (p=0.3340) and affective
(p=0.2234) descriptors. The perception of disability improved too, showing
an amelioration trend in Health Assessment Questionnaire-HAQ
(p=0.4301) and Mouth Handicap in Systemic Sclerosis scale-MHISS-
(p=0.9775).
Conclusion: Our results confirm the potential efficacy of AFG to treat
SSc skin complications and DUs. We reported an almost complete
healing of DUs and a promising improvement of skin thickness and hard-
ness both at hands and mouth, with good safety profiles. These clinical
results were reflected by the subjective improvement of patients’ well-
being. Population enlargement and extended FU is ongoing to identify
more responsive SSc subsets. Long term results with soft tissue biopsies
will give us further data to finally evaluate the efficacy of this approach
that aims to improve the care and quality of life of our SSc patients.
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Background: Systemic sclerosis (SSc) is a systemic autoimmune disease
characterized by microvascular damages and fibrosis. The main lesions of
SSc are peripheral circulation insufficiency, sclerodermia, and interstitial
pneumonia. Skin lesions are related to patient‘s ADL and QOL, however
there is no effective treatment for normalizing the disease state. Adipose-
derived stem cells (AdSCs) have recently been considered a useful treat-
ment tool for autoimmune disease because of their anti-inflammatory and
immunosuppressive effects (ref).
Objectives: We investigated the therapeutic effect of intravenous mouse
AdSCs (mAdSCs) transplantation in a SSc mouse model.
Methods: SSc was induced by bleomycin (BLM) in Balb/c mice, and the
mice were assigned in the following groups: 1. Control (BLM-SSc), 2.
mAdSCs (1.0×104 cells), 3. mAdSCs (1.0×105 cells). After the administra-
tion of BLM, mAdSCs were injected via a tail vein on day 7. The mice
were sacrificed at 14 days after mAdSCs injection, and the skins were
harvested for histological analysis.
Results: In mAdSCs (1.0×105 cells) group, thickening of skin, hydroxypro-
line content, infiltration of inflammatory cells, gene expression of inflam-
matory cytokines, and fibrotic factors were significantly reduced compared
with control group (Figure). But in mAdSCs (1.0×104 cells) group, there
were no reduction of them. mAdSCs did not accumulate in skin. The lev-
els of MMP-2, MMP-9, and COL1A1 mRNA expression at 21 days after
BLM administration were significantly lower in mAdSCs (1.0×105 cells)
group compared with those in control group.
Abstract THU0350 – Figure 1
Conclusion: Intravenous mAdSCs inhibited both skin inflammation and fib-
rosis of BLM-SSc mice in a dose-dependent manner.
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